Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 5/20 | 0.38 |
| ▸ | FGFR2 | P21802 | 5/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.36 |
| ▸ | AKT1 | P31749 | 2/20 | 0.35 |
| ▸ | MTOR | P42345 | 2/20 | 0.35 |
| ▸ | FAAH | O00519 | 4/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.34 |
| ▸ | ITK | Q08881 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6894934 | 0.85 | CHEK1 (0.37) | EGFRFGFR2HSP90AA1PIK3CAAKT1 | |
| SCHEMBL6894410 | 0.80 | KDM4E (0.41) | HSP90AA1PIK3CAAKT1MTORFAAH | |
| SCHEMBL7881694 | 0.79 | EGFR (0.36) | EGFRFGFR2HSP90AA1PIK3CAAKT1 | |
| SCHEMBL6893473 | 0.79 | KDM4E (0.42) | PIK3CAMTORFAAH | |
| SCHEMBL6891833 | 0.79 | PIK3CA (0.42) | PIK3CAMTOR | |
| SCHEMBL6894412 | 0.78 | PIK3CA (0.35) | EGFRFGFR2HSP90AA1PIK3CAAKT1 | |
| SCHEMBL6893056 | 0.78 | KDM4E (0.40) | HSP90AA1PIK3CAFAAH | |
| SCHEMBL584529 | 0.78 | HSP90AA1 (0.45) | HSP90AA1PIK3CAMTOR | |
| SCHEMBL7883143 | 0.76 | KDM4E (0.40) | EGFRFGFR2HSP90AA1PIK3CAAKT1 | |
| SCHEMBL6893328 | 0.76 | PIK3CA (0.40) | EGFRFGFR2HSP90AA1PIK3CAAKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-05-10 | — | — | US | disclosed |
| US-20110054013-A1 | TETRAHYDROPYRANOCHROMENE GAMMA SECRETASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110054013-A1 | TETRAHYDROPYRANOCHROMENE GAMMA SECRETASE INHIBITORS | BACE1, BACE2, PSEN1 | EGFR 4536/4885FGFR2 3710/4885HSP90AA1 2012/4885 |
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MTOR, RICTOR, RPTOR | EGFR 2799/4885FGFR2 1827/4885HSP90AA1 617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.